ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

Zymeworks Q4 Adj. EPS $4.71 Misses $4.84 Estimate, Sales $402.49M Beat $371.30M Estimate https://www.benzinga.com/news/earnings/23/03/31246389/zymeworks-q4-eps-4-65-misses-4-84-estimate-sales-402-49m-beat-371-30m-estimate

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results https://www.businesswire.com/news/home/20230307005535/en/Zymeworks-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-84-overall-survival-at-18-months-from-phase-2-trial-evaluating-zanidatamab-in-her2-expressing-metastatic-gastroesophageal-adenocarcinoma-301725785.html

🎈

https://www.conferencecalltranscripts.org/summary/?id=11707563 Major owner of Zymeworks Inc. just picked up 985,100 shares

Nette Bewegung nachbörslich....

Insider Buys Shares Worth $8M https://www.tipranks.com/news/zymeworks-nasdaqzyme-stock-insider-buys-shares-worth-8m

Zymeworks: Good Data, Lots Of Cash, Stagnant Stock https://seekingalpha.com/article/4569409-zymeworks-good-data-lots-of-cash-stagnant-stock Summary • Last month, ZYME presented strong data in HER2+ BTC. • Its Jazz collaboration has given it access to a lot of funds. • The stock is still stagnant, probably because the market feels ZYME lacks growth prospects. ...

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 https://www.businesswire.com/news/home/20230104005869/en/Zymeworks-Provides-Corporate-Update-on-Key-Strategic-Priorities-and-Outlook-for-2023 • Provides updated key priorities and focus on enterprise value framework • Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 • Announces additional financial guidance on expected cash runway; provides unaudited cash and cash resources balance as of December 31, 2022 • Announces recommended Phase 2 dose (RP2D) for zanidatamab zovodotin (ZW49) ... Based on current operating plans, we expect to have cash resources to fund research and development programs, as well as operations, through at least the end of 2026, and potentially beyond. ...

https://www.sec.gov/Archives/edgar/data/1937653/000092189523000006/0000921895-23-000006-index.htm

https://newsfilter.io/a/26ed65126e6bf06a7bb0f61edec86e59 Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-jazz-has-confirmed-opt-in-and-advances-partnership-for-zanidatamab-301707906.html

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 https://www.benzinga.com/analyst-ratings/upgrades/22/12/30146428/benzingas-top-ratings-upgrades-downgrades-for-december-20-2022 Upgrades ... According to Jefferies, the prior rating for Zymeworks BC Inc (NYSE:ZYME) was changed from Hold to Buy. In the third quarter, Zymeworks BC showed an EPS of $0.66, compared to $1.25 from the year-ago quarter. The current stock performance of Zymeworks BC shows a 52-week-high of $17.27 and a 52-week-low of $4.11. Moreover, at the end of the last trading period, the closing price was at $6.79. ...

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab https://www.businesswire.com/news/home/20221219005219/en/Zymeworks-Announces-Positive-Topline-Data-in-the-Pivotal-HERIZON-BTC-01-Trial-of-Zanidatamab • Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) • Pending receipt of regulatory approvals, zanidatamab has the potential to be the first HER2-targeted therapy for patients with BTC

🎈